Caitong International Asset Management Co. Ltd Increases Stock Position in Integra LifeSciences Holdings Corporation $IART

Caitong International Asset Management Co. Ltd boosted its stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 205.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,132 shares of the life sciences company’s stock after buying an additional 2,108 shares during the quarter. Caitong International Asset Management Co. Ltd’s holdings in Integra LifeSciences were worth $38,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Allianz Asset Management GmbH boosted its stake in shares of Integra LifeSciences by 53.7% in the second quarter. Allianz Asset Management GmbH now owns 229,904 shares of the life sciences company’s stock valued at $2,821,000 after purchasing an additional 80,290 shares during the period. New York State Teachers Retirement System boosted its stake in shares of Integra LifeSciences by 1.9% in the second quarter. New York State Teachers Retirement System now owns 87,660 shares of the life sciences company’s stock valued at $1,076,000 after purchasing an additional 1,662 shares during the period. CWM LLC boosted its stake in shares of Integra LifeSciences by 32.6% in the second quarter. CWM LLC now owns 8,834 shares of the life sciences company’s stock valued at $108,000 after purchasing an additional 2,170 shares during the period. Inspire Investing LLC boosted its stake in shares of Integra LifeSciences by 102.8% in the second quarter. Inspire Investing LLC now owns 31,721 shares of the life sciences company’s stock valued at $389,000 after purchasing an additional 16,076 shares during the period. Finally, Compass Financial Group INC SD purchased a new position in shares of Integra LifeSciences in the second quarter valued at approximately $172,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Stock Up 1.5%

Shares of NASDAQ:IART opened at $16.12 on Monday. The company has a quick ratio of 0.73, a current ratio of 1.23 and a debt-to-equity ratio of 1.18. Integra LifeSciences Holdings Corporation has a fifty-two week low of $11.06 and a fifty-two week high of $27.13. The firm’s 50 day moving average price is $14.72 and its 200 day moving average price is $13.92. The stock has a market cap of $1.26 billion, a price-to-earnings ratio of -2.47 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Thursday, July 31st. The life sciences company reported $0.45 earnings per share for the quarter, topping analysts’ consensus estimates of $0.43 by $0.02. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. The company had revenue of $415.61 million for the quarter, compared to analysts’ expectations of $395.06 million. During the same quarter last year, the company earned $0.63 earnings per share. The firm’s revenue for the quarter was down .6% on a year-over-year basis. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. As a group, equities research analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently commented on IART shares. Citigroup reissued a “sell” rating and issued a $12.00 price objective (up previously from $10.00) on shares of Integra LifeSciences in a research note on Tuesday, October 7th. Weiss Ratings reissued a “sell (d)” rating on shares of Integra LifeSciences in a research note on Saturday. Finally, Truist Financial set a $15.00 price objective on shares of Integra LifeSciences and gave the company a “hold” rating in a research note on Wednesday, October 15th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat, Integra LifeSciences presently has a consensus rating of “Reduce” and an average target price of $16.17.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.